The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | An insight into the current understanding of risk factors for CLL
Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, provides an insight into the risk factors identified for chronic lymphocytic leukemia (CLL). Having a family member with CLL is associated with a five- to seven-fold increase in risk. However, identifying the genes responsible for this has proven challenging. Agent orange and glyphosate herbicides have been identified as potential environmental risk factors, although the data are mixed, likely due to the retrospective nature of these studies. Finally, having precursor conditions such as monoclonal B-cell lymphocytosis (MBL) may be considered a risk factor. However, Dr Brown highlights that MBL is on the biological continuum of CLL and is likely associated with the same risk factors. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Loxo/Lilly, Pharmacyclics, Numab Therapeutics, Merck, Grifols Worldwide Operations, Kite, BeiGene, iOnctura, Alloplex Biotherapeutics, Hutchmed, Pfizer, Genentech/Roche, Abbvie, Acerta/AstraZeneca; Research Funding: Loxo/Lilly, TG Therapeutics, Gilead, BeiGene, iOnctura, SecuraBio, MEI Pharma.
